Addressing the Urgent Threat: Strategies for Combating Hard-To-Treat Bacterial Infections
In the United States, as many as 2 million patients are annually diagnosed with antibiotic-resistant Gram-positive or Gram-negative (GP/GN) infections. Unfortunately, the development of novel antibiotics has lagged dangerously behind the emergence of resistant infections, leaving these patients with limited treatment options. Recently, several novel antibiotics have been approved, and more are in the clinical pipeline, many of which have proven to be particularly effective in patients with harder-to-treat GP and/or GN pathogens. However, in the absence of the judicious use of these new antibiotics, acquired resistance to these new agents is inevitable. This archived symposium will provide participants with the opportunity to review the clinical utility of new and investigational antimicrobials while also focusing on strategies to promote careful, appropriate antibiotic utilization. Interactive patient case scenarios will allow clinicians to apply acquired knowledge of antibiotic use to real-world examples of treating patients with GP/GN infections.
This enduring activity is intended for infectious disease specialists, primary care clinicians, and microbiologists. No prerequisites required.
Upon completion of this activity, participants will be better able to do the following:
- RECOGNIZE factors that contribute to the growing local and global burden of GP/GN bacterial infections.
- ASSESS recently approved and investigational antibiotic treatment strategies for multi-drug resistant GP/GN infections.
- PROPOSE GN/GP treatment strategies for high-risk patients, considering pathogen and patient comorbidities.
- DESCRIBE components of an antimicrobial stewardship program and its implications in controlling the development of drug resistance.
DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Relationship Identified With:|
|George Sakoulas, MD (Chair)||Speakers' bureau and consultant/advisor: Allergan; The Medicines Company.|
|Thomas M. File, Jr, MD, MSc, MACP, FIDSA, FCCP||
Consultant/advisor: Allergan; The Medicines Company; Merck & Co Inc; Motif Bio; Pfizer Inc.
Grant/research support: Nabriva Therapeutics plc
|Yoav Golan, MD, MS, FIDSA||
Speakers' bureau: Allergan; The Medicines Company; Merck & Co Inc; Pfizer Inc; Theravance Biopharma.
Consultant/advisor: Achaogen, Inc; Allergan; Merck & Co Inc; The Medicines Company.
Grant/research support: Allergan and Merck & Co Inc.
|Jason M. Pogue, PharmD, BCPS-ID||
Speakers' bureau: Allergan; Merck & Co Inc; and The Medicines Company.
Consultant/advisor: Accelerate Diagnostics, Inc; Achaogen, Inc; Allergan; bioMérieux, Inc; Bionex Pharmaceuticals LLC; Merck & Co Inc; The Medicines Company; Shionogi Inc; Zavante Therapeutics, Inc.
Grant/research support: Merck & Co Inc.
|Warren E. Rose, PharmD, MPH||
Speakers' bureau and consultant/advisor: Theravance Biopharma and The Medicines Company.
Consultant/advisor: Visante Inc.
Grant/research support: Merck & Co Inc and Theravance Biopharma.
Non-faculty: Sandy Breslow; Leah Johnson; Marilu Kelly, MSN, RN, CNE; Alison Kemp; Bernard M. Abrams, MD; Lou Settembrino; Christina M. Ohnsman, MD; hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Allergan.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME CREDIT (PHYSICIANS)
The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE CREDIT (NURSES)
Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier ANCC accredited Provider Unit, and ASiM. EOCME is accredited by the ACCME to provide continuing medical education for physicians.
Earn 2.0 AMA PRA Category 1 Credits™ or 2.0 nursing education contact hours.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
TABLE OF CONTENTS
Overview and Activity Goals
George Sakoulas, MD
Growing Burden of Antimicrobial Resistance
Thomas M. File, Jr, MD, MSc, MACP, FIDSA, FCCP
Treatment Strategies: Managing At-Risk Patients and Preventing Resistance
Warren E. Rose, PharmD, MPH
Practical Aspects of Antimicrobial Stewardship
Jason M. Pogue, PharmD, BCPS-ID
Clinical Applications of New and Investigational Antimicrobials
Yoav Golan, MD, MS, FIDSA
Question and Answer Session
George Sakoulas, MD
Postassessment and Evaluation
Release date: 12/31/17
Expiration date: 12/30/18
Estimated time to complete: 120 minutes